Cancer Immunology, Immunotherapy

, Volume 59, Issue 9, pp 1401–1409

Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners

  • Xinmei Zhu
  • Beth A. Fallert-Junecko
  • Mitsugu Fujita
  • Ryo Ueda
  • Gary Kohanbash
  • Edward R. Kastenhuber
  • Heather A. McDonald
  • Yan Liu
  • Pawel Kalinski
  • Todd A. Reinhart
  • Andres M. Salazar
  • Hideho Okada
Original Article

DOI: 10.1007/s00262-010-0876-3

Cite this article as:
Zhu, X., Fallert-Junecko, B.A., Fujita, M. et al. Cancer Immunol Immunother (2010) 59: 1401. doi:10.1007/s00262-010-0876-3

Abstract

Stimulation of double-stranded (ds)RNA receptors can increase the effectiveness of cancer vaccines, but the underlying mechanisms are not completely elucidated. In this study, we sought to determine critical roles of host IFN-α and IFN-γ pathways in the enhanced therapeutic efficacy mediated by peptide vaccines and polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in the murine central nervous system (CNS) GL261 glioma. C57BL/6-background wild type (WT), IFN-α receptor-1 (IFN-αR1)−/− or IFN-γ−/− mice bearing syngeneic CNS GL261 glioma received subcutaneous (s.c.) vaccinations with synthetic peptides encoding CTL epitopes with or without intramuscular (i.m.) injections of poly-ICLC. The combinational treatment induced a robust transcription of CXCL10 in the glioma site. Blockade of CXCL10 with a specific monoclonal antibody (mAb) abrogated the efficient CNS homing of antigen-specific type-1 CTL (Tc1). Both IFN-αR−/− and IFN-γ−/− hosts failed to up-regulate the CXCL10 mRNA and recruit Tc1 cells to the tumor site, indicating non-redundant roles of type-1 and type-2 IFNs in the effects of poly-ICLC-assisted vaccines. The efficient trafficking of Tc1 also required Tc1-derived IFN-γ. Our data point to critical roles of the host-IFN-α and IFN-γ pathways in the modulation of CNS glioma microenvironment, and the therapeutic effectiveness of poly-ICLC-assisted glioma vaccines.

Keywords

CNS glioma Poly-ICLC Glioma vaccine Type-1 immune response Chemokine 

Abbreviations

BIL

Brain infiltrating lymphocyte

CNS

Central nervous system

mAb

Monoclonal antibody

GAA

Glioma-associated antigen

Tc1

CTL with type-1 phenotype

Supplementary material

262_2010_876_MOESM1_ESM.doc (20 kb)
Supplementary method (DOC 20 kb)
262_2010_876_MOESM2_ESM.tif (1.8 mb)
Supplementary method (TIFF 1.75 mb)
262_2010_876_MOESM3_ESM.tif (2.7 mb)
Supplementary method (TIFF 2.68 kb)
262_2010_876_MOESM4_ESM.tif (1.3 mb)
Supplementary method (TIFF 1.31 mb)
262_2010_876_MOESM5_ESM.tif (2.4 mb)
Supplementary method (TIFF 2.40 mb)

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Xinmei Zhu
    • 1
    • 2
  • Beth A. Fallert-Junecko
    • 3
  • Mitsugu Fujita
    • 1
    • 2
  • Ryo Ueda
    • 1
    • 2
  • Gary Kohanbash
    • 2
    • 3
  • Edward R. Kastenhuber
    • 2
  • Heather A. McDonald
    • 2
  • Yan Liu
    • 1
  • Pawel Kalinski
    • 4
  • Todd A. Reinhart
    • 3
  • Andres M. Salazar
    • 5
  • Hideho Okada
    • 1
    • 2
    • 4
    • 6
  1. 1.Department of Neurological SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Brain Tumor ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Department of Infectious Diseases/Microbiology, Graduate School of Public HealthUniversity of PittsburghPittsburghUSA
  4. 4.Department of Surgery and ImmunologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  5. 5.Oncovir Inc.Washington DCUSA
  6. 6.G12a Research Pavilion at Hillman Cancer CenterPittsburghUSA

Personalised recommendations